SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing significant momentum and volatility as investors react to positive FDA briefing documents regarding its mRNA flu vaccine candidate ahead of a key advisory committee vote. The community is actively debating the stock's long-term growth potential through its expanding oncology and rare disease pipeline, while also tracking high short interest that has fueled speculation of a potential short squeeze.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Churchill Capital Corp XI - Ordinary Shares - Class A

Churchill Capital Corp XI is trending due to significant institutional accumulation and the building momentum surrounding the Agility Robotics commercialization narrative. Community sentiment remains focused on the potential for a major re-rating as investors compare the firm's strategic industrial partnerships to successful past robotics and infrastructure plays.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is seeing heightened community engagement driven by anticipation of a potential buyout, as investors weigh the impact of recent product approvals and the company's aggressive pipeline development in the GLP-1 adjunct space. While bullish participants point to valuable clinical assets as prime acquisition targets, others remain focused on navigating volatility and debating the impact of management's confrontational regulatory strategy on future valuation.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is currently a focal point for investors debating whether its aggressive acquisition strategy and high short interest signal an impending rebound or further downside following heavy share dilution. The community is sharply divided, with bulls pointing to the company's expanding backlog and defense partnerships, while vocal critics are focused on insider selling and the stock's poor recent performance.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific is currently trending as investors debate whether the recent double-digit share price slide represents a structural breakdown or a deep-value accumulation opportunity following an accelerated share buyback and cautious management guidance. Community sentiment is heavily polarized, with many retail investors expressing frustration over the persistent downtrend while active traders are aggressively positioning in LEAPs and accumulating common equity, betting on a technical bounce driven by the firm's core medical technology fundamentals.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is experiencing significant volatility and heavy volume as traders debate the company's pivot toward becoming an AI infrastructure backbone through its Private Connectivity Fabric and recent strategic acquisitions. While bulls point to massive hyperscaler deal potential and a critical fiber footprint as long-term catalysts, the stock faces intense selling pressure from institutional shorting and concerns regarding balance sheet constraints and legacy business decline.

WorldFinancial

Investors are actively debating the future of World Liberty Financial ($WLFI.X) amid sharp criticism of its performance and vocal community accusations of a potential "rug pull" or grift tied to political branding. While some participants are aggressively calling for a rebound driven by anticipated token burns and supply shocks, others are heavily focused on the significant losses incurred and questioning the project's long-term legitimacy.

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Nuvation Bio Inc - Ordinary Shares - Class A

Nuvation Bio is experiencing significant market volatility surrounding its earnings report as investors weigh the company's Ibtrozi commercial launch against concerns over patient retention in late-line treatments. Community sentiment remains split between long-term optimism regarding a potential buyout catalyst and frustration over recent downward price pressure and insider trading activity.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Abeona Therapeutics is trending as investors react to the company's shift from development to commercialization, with community discussion centered on the rollout of ZEVASKYN and anticipation for Q1 earnings. The conversation is heavily focused on potential short squeeze dynamics driven by high short interest, institutional accumulation, and the expectation of revenue acceleration through an expanding network of Qualified Treatment Centers.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma is seeing significant investor interest driven by its specialized semiconductor technology, which is being positioned as a key solution to scaling bottlenecks in AI infrastructure and data center communication. The community is actively debating the company's path to commercialization, with intense focus on recent executive hires, non-dilutive government contracts, and the potential impact of high short interest on future price volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ConocoPhillips (COP) Stock Moves 1.46%: What You Should Know

The latest trading day saw ConocoPhillips (COP) settling at $104.73, representing a +1.46% change from its previous close.

Can ExxonMobil's Upstream Business Thrive With Oil Below $70?

XOM can continue Permian production with WTI below $70, as prices remain above shut-in levels and output growth plans stay on track.

ConocoPhillips or Occidental Petroleum: Which Oil Stock Should You Buy Now?

Key PointsConocoPhillips is a global oil giant with operations spanning 14 different countries...

ConocoPhillips (COP) is a Top-Ranked Value Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

2 Oil Stocks Still Worth Buying With Oil Down to $70 a Barrel

Key PointsBP and ConocoPhillips have tightened their spending to increase margins...

ConocoPhillips to hold second-quarter earnings conference call on Thursday, Aug. 6

ConocoPhillips (NYSE: COP) will host a conference call webcast on Thursday, Aug. 6, 2026, at 12:00 p.m. Eastern time to discuss second-quarter 2026 financial and operating results. The companys financial and operating results will be released before the market opens on Aug. 6. To access the...

ConocoPhillips (COP) Registers a Bigger Fall Than the Market: Important Facts to Note

In the latest trading session, ConocoPhillips (COP) closed at $106.92, marking a -2.77% move from the previous day.

Why Investors Need to Take Advantage of These 2 Oils and Energy Stocks Now

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Is the Current Pricing Environment Favorable for BP's Upstream?

BP's upstream outlook looks encouraging as WTI prices stay above $70 and the company reports 14 discoveries since the start of 2025.

Can ExxonMobil's Upstream Business Thrive at Current Oil Prices?

XOM's upstream business could gain from strong WTI crude prices, with Permian and Guyana assets supporting production growth and earnings.

ConocoPhillips is an exploration and production company, which engages in the exploration, production, transport, and marketing of crude oil, bitumen, and natural gas. It operates through the following geographical segments: Alaska, Lower 48, Canada, Europe, Middle East, and North Africa, Asia Pacific, and Other International. The Alaska segment explores for, produces, transports and markets crude oil, natural gas and NGLs. The Lower 48 segment consists of operations located in the 48 contiguous U.S. states and the Gulf of Mexico. The Canada segment refers to oil sands development in the Athabasca Region of northeastern Alberta and a liquids-rich unconventional play in western Canada. The Europe, Middle East, and North Africa segment includes operations in the Norwegian sector of the North Sea, the Norwegian Sea, Qatar, Libya, Equatorial Guinea and commercial and terminalling operations in the U.K. The Asia Pacific segment focuses on explorations and product operations in China, Indonesia, Malaysia, and Australia. The Other International segment handles exploration activities in Columbia and Argentina. The company was founded by Isaac Elder Blake on November 25, 1875 and is headquartered in Houston, TX.

Conoco Phillips

CVX, XOM, COP Slip Overnight As Trump Orders DOJ Probe Into Big Oil's Gasoline Prices: 'Customers Are Being Gouged'

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

COPConoco Phillips

Fundamentals

Latest COP News